0 rating

The Economics of Rheumatoid Arthritis Management

Daniel H Solomon, MD, MPH1, and Arthur F Kavanaugh, MD2
Evaluating the cost-effectiveness of therapies in rheumatoid arthritis (RA) has become increasingly important as the costs of medications rise. The authors of this article review the current state of pharmacoeconomics in RA.
Return to top

RELATED ARTICLES

Anti-Citrullinated Protein Antibodies as a Risk Factor for Rheumatoid Arthritis
Diane van der Woude, MD, and Tom WJ Huizinga, MD, PhD
International Journal of Advances in Rheumatology
A Question and Answer Approach to Rheumatoid Arthritis Disease Activity
Daniel Aletaha, MD, and Josef Smolen, MD
International Journal of Advances in Rheumatology
Cardiovascular Risk Factors in Rheumatoid Arthritis
Hilal Maradit Kremers, MD, MSc, Cynthia S Crowson, MS, and Sherine E Gabriel, MD, MSc
CML Rheumatology
Serum Autoantibodies in Rheumatoid Arthritis
Raimon Sanmartí, MD, Maria Victoria Hernández, MD, José A Gómez-Puerta, MD, Eduard Graell, MD, and Juan D Cañete, MD, PhD
International Journal of Advances in Rheumatology
Cardiovascular Aspects of Rheumatoid Arthritis
Michael T Nurmohamed, MD, PhD
International Journal of Advances in Rheumatology

LATEST ARTICLES